Perspective on strengthening dementia prevention and control system: a comprehensive framework for national health

Bin Cong , Hengge Xie , Yongan Sun , Jingnian Ni , Jing Shi , Mingqing Wei , Fuyao Li , Huali Wang , Luning Wang , Bin Qin , Jing Cheng , Demin Han , Wei Xiao , Boli Zhang , Jinzhou Tian , on behalf of the Key Project Team of the Department of Medicine and Health of the Chinese Academy of Engineering

Front. Med. ›› 2025, Vol. 19 ›› Issue (5) : 865 -870.

PDF (1097KB)
Front. Med. ›› 2025, Vol. 19 ›› Issue (5) : 865 -870. DOI: 10.1007/s11684-025-1154-2
PERSPECTIVE

Perspective on strengthening dementia prevention and control system: a comprehensive framework for national health

Author information +
History +
PDF (1097KB)

Cite this article

Download citation ▾
Bin Cong, Hengge Xie, Yongan Sun, Jingnian Ni, Jing Shi, Mingqing Wei, Fuyao Li, Huali Wang, Luning Wang, Bin Qin, Jing Cheng, Demin Han, Wei Xiao, Boli Zhang, Jinzhou Tian, on behalf of the Key Project Team of the Department of Medicine and Health of the Chinese Academy of Engineering. Perspective on strengthening dementia prevention and control system: a comprehensive framework for national health. Front. Med., 2025, 19(5): 865-870 DOI:10.1007/s11684-025-1154-2

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Ministryof Civil Affairs of ChinaNationalWorking Commission on Aging. Annual report on the development of national aging undertakings 2022. 2023. Available at the website of the State Council of the People’s Republic of China (in Chinese)

[2]

The elderly will account for about one-third of China’s total population by 2050. 2018. Available at the website of the State Council of the People’s Republic of China (in Chinese)

[3]

World Health Organization. Global status report on the public health response to dementia. Geneva: World Health Organization, 2021

[4]

Alzheimer’s Association . 2022 Alzheimer’s disease facts and figures. Alzheimers Dement 2022; 18(4): 700–789

[5]

GauthierSWebsterCServaesSMoraisJARosa-NetoP. World Alzheimer report 2022: life after diagnosis: navigating treatment, care and support. London, England: Alzheimer’s Disease International. 2022

[6]

Ren R , Qi J , Lin S , Liu X , Yin P , Wang Z , Tang R , Wang J , Huang Q , Li J , Xie X , Hu Y , Cui S , Zhu Y , Yu X , Wang P , Zhu Y , Wang Y , Huang Y , Hu Y , Wang Y , Li C , Zhou M , Wang G . The China Alzheimer Report 2022. Gen Psychiatr 2022; 35(1): e100751

[7]

Alzheimer’s Association . 2024 Alzheimer’s disease facts and figures. Alzheimers Dement 2024; 20(5): 3708–3821

[8]

Liu S , Li C , Shi Z , Wang X , Zhou Y , Liu S , Liu J , Yu T , Ji Y . Caregiver burden and prevalence of depression, anxiety and sleep disturbances in Alzheimer’s disease caregivers in China. J Clin Nurs 2017; 26(9–10): 1291–1300

[9]

Sallim AB , Sayampanathan AA , Cuttilan A , Ho R . Prevalence of mental health disorders among caregivers of patients with Alzheimer disease. J Am Med Dir Assoc 2015; 16(12): 1034–1041

[10]

Jia J , Wei C , Chen S , Li F , Tang Y , Qin W , Zhao L , Jin H , Xu H , Wang F , Zhou A , Zuo X , Wu L , Han Y , Han Y , Huang L , Wang Q , Li D , Chu C , Shi L , Gong M , Du Y , Zhang J , Zhang J , Zhou C , Lv J , Lv Y , Xie H , Ji Y , Li F , Yu E , Luo B , Wang Y , Yang S , Qu Q , Guo Q , Liang F , Zhang J , Tan L , Shen L , Zhang K , Zhang J , Peng D , Tang M , Lv P , Fang B , Chu L , Jia L , Gauthier S . The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimers Dement 2018; 14(4): 483–491

[11]

World Health Organization. Inclusion of multisectoral collaboration as a guiding principles of the dementia plan. 2024. Available at the website of WHO

[12]

National Health Commission of the P. R. China. Notice on carrying out action to promote prevention and treatment of dementia in the elderly (2023–2025). 2023. Available at the website of the State Council of the People’s Republic of China (in Chinese)

[13]

GauthierSRosa-NetoPMoraisJAWebsterC. World Alzheimer report 2021: journey through the diagnosis of dementia. London, England: Alzheimer’s Disease International, 2021

[14]

Qi S , Zhang H , Guo H , Wu J , Wang Z . Undetected dementia in community-dwelling older people — 6 provincial-level administrative divisions, China, 2015−2016. China CDC Wkly 2020; 2(38): 731–735

[15]

OECD. Care Needed: Improving the Lives of People with Dementia. Paris: OECD Publishing, 2018

[16]

Department of Planning Development and Information Technology. Statistical Bulletin of China’s Health Care Development 2022. 2023. Available at the website of the NHC (in Chinese)

[17]

Alzheimer’s Disease Chinese. ADC-Baidu “Memory Clinic Map” update launched. 2023. Available at the website of the ADC (in Chinese)

[18]

Tian JZ , Xie HG , Wang LN , Wang YH , Wang HL , Shi J , Qin B , Fan DS , Ni JN , Sun YA . Chinese guidelines for diagnosis and treatment of Alzheimer’s disease 2020. Chin J Geriatr (Zhonghua Lao Nian Yi Xue Za Zhi) 2021; 40(3): 269–283

[19]

Budd Haeberlein S , Aisen PS , Barkhof F , Chalkias S , Chen T , Cohen S , Dent G , Hansson O , Harrison K , von Hehn C , Iwatsubo T , Mallinckrodt C , Mummery CJ , Muralidharan KK , Nestorov I , Nisenbaum L , Rajagovindan R , Skordos L , Tian Y , van Dyck CH , Vellas B , Wu S , Zhu Y , Sandrock A . Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis 2022; 9(2): 197–210

[20]

Knopman DS , Jones DT , Greicius MD . Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement 2021; 17(4): 696–701

[21]

van Dyck CH , Swanson CJ , Aisen P , Bateman RJ , Chen C , Gee M , Kanekiyo M , Li D , Reyderman L , Cohen S , Froelich L , Katayama S , Sabbagh M , Vellas B , Watson D , Dhadda S , Irizarry M , Kramer LD , Iwatsubo T . Lecanemab in early Alzheimer’s disease. N Engl J Med 2023; 388(1): 9–21

[22]

Sims JR , Zimmer JA , Evans CD , Lu M , Ardayfio P , Sparks J , Wessels AM , Shcherbinin S , Wang H , Monkul NE , Collins EC , Solomon P , Salloway S , Apostolova LG , Hansson O , Ritchie C , Brooks DA , Mintun M , Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators . Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023; 330(6): 512–527

[23]

XiaoJLiJWangJZhangXWangCPengGHuHLiuHLiuJShenLZhangNYanNMaQXuWLiaoZRenRWangMYuETianJWangHSunYAXieHWangG. 2023 China Alzheimer’s disease: facts and figures. Human Brain 2023; 2(3): 1-13

[24]

Tian Y . Care policies for elders with mental incapacity in Japan and South Korea and lessons we can learn. J Aging Sci Res (Lao Ling Ke Xue Yan Jiu) 2019; 7(9): 68–79

RIGHTS & PERMISSIONS

Higher Education Press

AI Summary AI Mindmap
PDF (1097KB)

279

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/